Alvotech (ALVO) said Wednesday that it expects potential US tariffs on imported pharmaceuticals to have little effect on its 2025 revenue.
The company said its biosimilars, made in Iceland, would face a minimum tariff of 10%, translating to less than 1% of projected product revenue.
Under contract terms, the company said customers are responsible for all costs of transport and import duties to the US, which are therefore not expected to be paid by Alvotech.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.